John Libbey Eurotext

Bulletin du Cancer


Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers Volume 92, issue 9, Septembre 2005


See all figures

Hôpital Arnaud de Villeneuve, Inserm U540, 191, avenue du Doyen Giraud, 34295 Montpellier Cedex 5, Institut de génomique fonctionnelle, CNRS UMR 5203, Inserm U661, 141, rue de la Cardonille, 34094 Montpellier Cedex 5

Recent advances in proteomics offer opportunities to rapidly identify new biomarkers or pattern of markers for the early detection and diagnosis of cancer and to monitor the therapeutic efficacy and toxicity of treatments used to improve long-term survival of patients. The surfaced-enhanced laser desorption ionization/time-of-flight (Seldi-Tof) mass spectrometry is certainly one of the most promising approaches to achieve these goals. In this paper we will provide an overview of the studies that have used this new technology for the early diagnosis of human cancer.